financetom
Business
financetom
/
Business
/
Okta Business Momentum 'Slightly Improving' as Security Breach Impact Fades, Wedbush Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Okta Business Momentum 'Slightly Improving' as Security Breach Impact Fades, Wedbush Says
May 29, 2024 9:44 AM

12:19 PM EDT, 05/29/2024 (MT Newswires) -- Okta's ( OKTA ) business momentum is stable to slightly improving based on feedback from the company's partners as the impact of the October 2023 security breach starts to fade, Wedbush said in a note Wednesday.

The risk/reward for Okta ( OKTA ) heading into its fiscal Q1 print is neutral to slightly positive, "given where we believe the numbers could end up and what the stock is pricing in at current levels," the investment firm said.

Wedbush said Okta ( OKTA ) typically beats the high end of its guide and that fiscal Q1 revenue of about $624 million seems doable while contracted remaining performance obligations, or cRPO, are estimated at $1.94 billion, both above the company's guidance and consensus.

Although there's a slight risk to Q2 cRPO guidance, Okta's ( OKTA ) performance is strong, and its stock is reasonably valued, the firm added.

"Given reasonable buyside expectations, good checks and valuation not too stretched, we believe the downside risk is limited," Wedbush said in the note.

Wedbush maintained an outperform rating on the company's stock with a price target of $130.

Price: 95.63, Change: -0.52, Percent Change: -0.54

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Regeneron Pharmaceuticals, Sanofi Say Dupixent FDA Application Decision Delayed by 3 Months
Regeneron Pharmaceuticals, Sanofi Say Dupixent FDA Application Decision Delayed by 3 Months
May 31, 2024
04:49 AM EDT, 05/31/2024 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) and Sanofi ( SNY ) said Friday the US Food and Drug Administration has extended until Sept. 27 the action date on the biologics license application for Dupixent as a supplemental maintenance treatment in adults with uncontrolled chronic obstructive pulmonary disease. The three-month extension comes after the FDA...
--TFS Financial Maintains Dividend at $0.2825 per Share, Payable on June 25 to Shareholders of Record on June 11
--TFS Financial Maintains Dividend at $0.2825 per Share, Payable on June 25 to Shareholders of Record on June 11
May 31, 2024
04:58 AM EDT, 05/31/2024 (MT Newswires) -- Price: 12.78, Change: -0.31, Percent Change: -2.37 ...
American International Group Prices Secondary Offering of Corebridge Financial Targeting $876 Million in Gross Proceeds
American International Group Prices Secondary Offering of Corebridge Financial Targeting $876 Million in Gross Proceeds
May 31, 2024
04:49 AM EDT, 05/31/2024 (MT Newswires) -- American International Group ( AIG ) said Thursday it priced a secondary offering of Corebridge Financial ( CRBG ) common shares at $29.20 per share. As the selling stockholder, American International has offered 30 million common shares out of about 608 million shares outstanding of Corebridge Financial ( CRBG ), targeting gross proceeds...
Prelude Therapeutics Files for $400 Million Mixed Shelf
Prelude Therapeutics Files for $400 Million Mixed Shelf
May 31, 2024
04:54 AM EDT, 05/31/2024 (MT Newswires) -- Prelude Therapeutics ( PRLD ) filed Thursday a registration statement covering the potential sale of up to $400 million of securities from time to time. The securities include common stock, preferred stock, debt securities, warrants, subscription rights and units. Unless otherwise provided in a prospectus supplement, the company said it expects to use...
Copyright 2023-2026 - www.financetom.com All Rights Reserved